Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 6/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.34 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359589 | 0.95 | PLA2G2A (0.40) | PLA2G2APLA2G10PLA2G1BPLA2G5KIF11 | |
| SCHEMBL17359595 | 0.86 | ALDH1A1 (0.41) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G4B | |
| SCHEMBL17357645 | 0.82 | KIF11 (0.44) | KIF11SLC6A1SLC6A11KCNH2AHR | |
| SCHEMBL17358593 | 0.81 | KIF11 (0.43) | KIF11SLC6A1SLC6A11KCNH2AHR | |
| SCHEMBL17359590 | 0.79 | PLA2G2A (0.40) | PLA2G2APLA2G10PLA2G1BPLA2G5KIF11 | |
| SCHEMBL17359608 | 0.78 | PLA2G2A (0.37) | PLA2G2APLA2G10PLA2G1BPLA2G5KIF11 | |
| SCHEMBL9508740 | 0.78 | KIF11 (0.49) | KIF11SLC6A1SLC6A11CASRKCNH2 | |
| SCHEMBL17357648 | 0.78 | KIF11 (0.42) | KIF11SLC6A1SLC6A11KCNH2AHR | |
| SCHEMBL24115310 | 0.76 | KIF11 (0.43) | PLA2G2APLA2G10PLA2G1BPLA2G5KIF11 | |
| SCHEMBL15895042 | 0.76 | PLA2G2A (0.40) | PLA2G2APLA2G10PLA2G1BPLA2G5KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015200219-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200205-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | PLA2G2A 2939/4885PLA2G10 2487/4885PLA2G1B 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.